{
    "Trade/Device Name(s)": [
        "Tina-quant\u00ae C-Reactive Protein IV"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K192072",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083444"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DCN"
    ],
    "Summary Letter Date": "August 20, 2019",
    "Summary Letter Received Date": "August 22, 2019",
    "Submission Date": "January 10, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.5270"
    ],
    "Regulation Name(s)": [
        "C-reactive protein immunological test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "immunology"
    ],
    "Analyte(s)": [
        "C-Reactive Protein (CRP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Lithium heparin tube",
        "Serum tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas c systems",
        "cobas c 501 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric assay",
        "Particle enhanced immunoturbidimetric"
    ],
    "Methodologies": [
        "Turbidimetric measurement",
        "Immunochemical detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Tina-quant\u00ae C-Reactive Protein IV, a particle enhanced immunoturbidimetric assay for in vitro quantitative determination of CRP in human serum and plasma using cobas c systems.",
    "Indications for Use Summary": "In vitro quantitative determination of C-reactive protein in human serum and plasma on cobas c systems to aid in evaluation of injury to body tissues.",
    "fda_folder": "Immunology"
}